After 14 Days On Market, Suglat Prescriptions At Same Level As Januvia: JMRI
This article was originally published in PharmAsia News
Executive Summary
Fourteen days after it was released in Japan, prescriptions figures of the oral hypoglycemic SGLT-2 inhibitor Suglat (ipragliflozin) were roughly at the same level as DPP-4 inhibitor Januvia (sitagliptin) two weeks after it was released in 2009, according to the Japan Medical Information Research Institute.